Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
We want to make a comparison of PD-1 inhibitor combined with progesterone versus progesterone
alone in the treatment of early stage endometrial cancer patients who want to preserve
fertility.